A ~$700bn global hyperscaler capex wave is re-rating India's fibre and compute suppliers; optical-fibre and AI-server names are guiding to data-centre-led demand visibility that didn't exist a year ago.

Avg read 7.1·8 covered · scores as of Q2 FY27 · 1 provisional

The split has happened: Syrma's Q1 FY27 print jumped to 8.2 and it now expects to beat its 35%+ growth and 10.5-11% margin guide; Avalon raised FY27 growth to 26-30%; Aimtron guides a 40-50% CAGR with a Rs 112 cr data-centre UPS order; Vinyas sees FY27 inflows 25-30% above FY26. Centum (flat at 6.1) and the below-cut names are the laggards. The watch item is component supply: West Asia disruptions and the AI-driven memory-chip shortage.

Avg read 6.7·9 covered · scores as of Q2 FY27

DAC approvals hit a record ~Rs 6.7 lakh crore in FY26, but the big contracts (P-75I, QRSAM, next-gen corvettes) were still unsigned into Q2 FY27 and PSU order inflows fell last year. Watch conversion, not announcements.

Avg read 7.3·8 covered · scores as of Q2 FY27

Gold near record prices has not broken demand: Kalyan held its FY27 plan of 84 Kalyan and 50 Candere showrooms with wedding demand resilient through a 20% price dip, and Goldiam's US lab-grown share sits at 40-60% of major retailers with double-digit finished-jewellery growth. Organised jewellery and luxury-watch retail (Ethos, KDDL) keep taking share from the unorganised trade; watch margins (Kalyan guided flat PBT margin) and lab-grown pricing.

Avg read 6.9·6 covered · scores as of Q2 FY27

CEA's March 2026 plan maps ~Rs 7.9 lakh crore of transmission spend to FY36 with HVDC rising to ~120 GW; 400 kV-plus transformers and reactors stay capacity-constrained. Q1 FY27 tenders slowed on raw-material inflation and HVDC packages slipped, so watch awards, not the pipeline.

Avg read 7.2·9 covered · scores as of Q2 FY27 · 1 provisional

Q1 FY27 was a chemicals beat, but driven by refrigerant-gas pricing, crude-linked pass-through and new capacity at specific names, not a cycle turn; Chinese oversupply still caps agro and commodity-specialty pricing. Company-by-company, not sector-wide.

Avg read 6.7·7 covered · scores as of Q2 FY27

Waaree's Q1 FY27 print rose to 8.1 on an FY27 EBITDA guide of Rs 7,000-7,700 cr and a cell ramp to 1.5 GW a quarter by Q3; Suzlon's fell to 5.4 as 10-20% of Q1 deliveries slipped, with the 17-18% margin guide held and the street still at 73% upside (Motilal, 12 Oct 2026). Bondada guides 60-70% growth off a Rs 7,147 cr book (a Rs 1,154 cr October order = 38% of mcap). Demand is not the question here; execution and margins are.

Avg read 7.3·4 covered · scores as of Q2 FY27

Pharma earnings lagged in Q1 FY27 even as the sector led the year's rally; CDMO/CRAMS names are the reason, converting innovator deal wins in biologics, peptides, ADCs and GLP-1 intermediates on capacity already built. Risk is execution on fresh capacity.

Avg read 6.6·9 covered · scores as of Q2 FY27